Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Pancreatic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Icahn School of Medicine at Mount Sinai, New York, New York, United States
Contact: Study coordinator (Katherine Vandris) · Katherine.Vandris@mssm.edu
Contact: Study coordinator (Deirdre Cohen, MD) · Deirdre.Cohen@mssm.edu
Contact: Principal Investigator (Deirdre Cohen)

Study leads

Deirdre Cohen, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Colorectal Cancer · Metastatic Pancreatic Cancer · Metastatic Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Bethesda, United States

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE1, PHASE2

Buffalo, United States

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Ductal Adenocarcinoma · Resectable Pancreatic Adenocarcinoma · Stage I Pancreatic Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE2

Atlanta, United States

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer Metastatic

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shenzhen, China